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Nitrogen-containing heterocycles represent a major source of pharmacological probes and drug
candidates. To extend their molecular diversity and their potential biological activities, it is of importance
to design and synthesize new N-heterocyclic scaffolds. Therefore, aza-diketopiperazines (aza-DKPs), the
aza analogues of well-known 2,5-diketopiperazines (DKPs), emerged as a promising new scaffold.
Although the first synthesis of an aza-DKP dates from 1951, significant developments have been made
during the last decade. This feature article summarizes the different synthetic strategies to access and
functionalise aza-DKPs. Their biological properties and potential applications in medicinal chemistry and
drug discovery are discussed as well.Fig. 1 Examples of bioactive compounds with a DKP skeleton: tadalafil
(PDE5 inhibitor), retosiban (oxytocin receptor antagonist) and plina-
bulin (tubulin polymerisation inhibitor).1. Introduction
A large majority of FDA-approved drugs contain a heterocycle in
their structure.1,2 Amongst these heterocycles, 2,5-diketopiper-
azines (DKPs) represent a privileged scaffold in medicinal
chemistry3–7 as well as in organic synthesis.5–8 Obtained from
the double condensation of two amino acids, DKPs are the
smallest cyclic peptides with nonetheless different properties
from their linear counterparts.9 At the same time, DKPs contain
a six membered ring like many drug molecules, unlike the
macrocycles that arise from the cyclization of larger peptides.
Due to the ubiquitous availability of amino acids, DKPs are
highly represented among natural bioactive molecules extracted
from plants, fungi, bacteria and mammals as well as syntheti-
cally prepared in the laboratory.10,11 The privileged nature of the
DKP scaffold can be seen from the biological activities associ-
ated with DKPs against different targets including GPCRs such
as the GABAergic,12 serotoninergic 5HT1A,13 and oxytocin
receptors and enzymes such as phosphodiesterase 5 (PDE5).
Several DKP compounds (Fig. 1) have advanced to clinical
development, among which the PDE5 inhibitor tadalal
(Cialis™) 1 (ref. 14) received FDA approval for the treatment of
erectile dysfunction. Meanwhile, retosiban 2 (ref. 15–17) and
plinabulin 3 (ref. 18) reached Phase III clinical trials for preterm
labour and cancer respectively.
The DKP scaffold can be conveniently diversied at four
different positions, with substituents oriented along different
directions in space, by using a variety of natural and unnaturaloire d’Innovation Thérapeutique, LabEX
R 7200, Strasbourg F-67000, France.
@unistra.fr
lia, Norwich Research Park, Norwich NR4
43370amino acid building blocks. Furthermore, the availability of
chiral amino acids (oen as both enantiomers) enables the
chirality at the two stereocenters to be xed. However, the
concept of privileged scaffolds19,20 shows limits intrinsically
linked with the use of over-represented structures, thus
reducing molecular diversity and patentability. Synthetic
chemists then reoriented towards rarer and unprivileged scaf-
folds with physicochemical properties that are compatible with
the discovery of new drug candidates and overcome the disad-
vantages mentioned above. Indeed, as demonstrated by Pitt's
group at Celltech,21 many heterocycles are yet to be synthesised:
amongst the 25 000 heterocyclic structures theoreticallyFig. 2 Comparison between DKPs and aza-DKPs.
This journal is © The Royal Society of Chemistry 2020


































































































View Article Onlinegenerated as potentially of interest for medicinal chemists, only
1700 had been synthesised with around 5 to 10 new scaffolds
being published each year. Based on these considerations, our
laboratory in collaboration with A. Ganesan focused on 1,2,4-
triazine-3,6-diones or aza-diketopiperazines (aza-DKPs) as
underprivileged analogues of DKPs with potentially similar or
better properties. These compounds can be envisioned as
arising from DKPs through scaffold hopping with the replace-
ment of a sp3 carbon atom by a sp2/sp3 nitrogen atom (Fig. 2).
Compared to the DKP, there are now three nitrogen atoms in
the ring system (hence the title of our review) with the oppor-
tunity to functionalise these positions through the choice of
starting materials or late stage reactions aer formation of the
heterocycle.
Such a modication involving the replacement of a peptide
a-carbon by an extra nitrogen has already been studied in the
backbone of linear polypeptides to give so called ‘aza-peptides’.
These modied peptides showed a attening of the spatial
arrangement of the substituents linked to the new nitrogen
atom while having the potential to exhibit adaptive chirality.22,23
This structural difference was also observed by us in the
comparison between a DKP and its aza-DKP analogue by X-ray
crystallography (Fig. 3).24 The DKP 4 exhibits a general planar
conformation of the ring, in this case with dihedral angles
between C1–C2 and N1–C3 or C1–N2 and C4–C3 being close to
20. On the other hand, the aza-DKP 5, with the introduction of
the third sp2/sp3 nitrogen atom, displays a similar behaviour
between C1–N1 and N2–C2 with an angle of 19. However, the
dihedral angle between C2–C3 and N3–C1 is here importantly
deviated towards a less planar arrangement with a dihedral
angle of 37. Furthermore, NMR experiments performed in
CDCl3 and DMSO-d6 and at several temperatures showed
a relatively small variation of the different chemical shis
conrming the rigidity of this new scaffold in solution. Thus,
this new heterocycle exhibits similar drug-like properties to
a DKP (low molecular weight, 4 diversity points, in agreement
with Lipinski's rules25) while orienting slightly differently its
substituents in space offering different possible interactions
with biological targets.Fig. 3 X-ray crystallographic structure of DKP 4 (CCDC 1520134) and
its aza-DKP analogue 5 (CCDC 1520133).
This journal is © The Royal Society of Chemistry 2020A review of the literature showed that in 2020, only about 300
molecules exhibiting an aza-DKP skeleton were found in the
Scinder® database whereas around 40 000 DKPs were
described, making aza-DKPs an underprivileged scaffold by
comparison. To date, no reviews concerning this family of
compounds have been published. Thus, we gathered all the
publications dealing with the syntheses and properties of aza-
DKPs. We rst classied the different synthetic strategies
according to the precursor involved in the cyclisation: the
semicarbazide or the 2-aminohydrazide (Scheme 1). We then
listed the different methods for the introduction of the different
substituents at the four available ring positions either during
the synthesis or via post-functionalisation. The nal part of our
review focuses on the physicochemical properties and biolog-
ical activities of aza-DKPs.2. Synthetic strategies
2.1. Via a cyclisation of a 2-aminohydrazide
This strategy was based on the use of a 2-aminohydrazide
derivative and the introduction or the formation of a suitable
functional group (carbamate, carbazate or isocyanate) leading,
through a cyclisation, to the urea moiety present in an aza-DKP
(Scheme 2).
The rst synthesis to obtain aza-diketopiperazines was rst
published by Schlögl and Korger in 1951,26 and was performed
in two steps from an amino acid precursor in racemic or
enantiopure series. The carbamate derivatives of the amino acid
6 was treated with hydrazine monohydrate to form in situ the 2-
aminoacetohydrazide derivatives 7, which then cyclised onto
the benzyl carbamate through an addition/elimination process
to give the desired triazines 8 in yields ranging from 26 to 71%
(Scheme 3). Nonetheless, the authors noted a total loss of
optical activity in the nal aza-DKP when enantiopure amino
acids (L-leucine and L-tyrosine) were used. This racemisationScheme 2 Aza-DKP retrosynthesis via the cyclisation of a 2-
aminoacetohydrazine.
RSC Adv., 2020, 10, 43358–43370 | 43359
Scheme 3 First aza-DKP synthesis.
Scheme 4 Bicyclic aza-DKP first example.
Scheme 7 Syntheses of aza-DKPs fused with N-heterocycles.



































































































View Article Onlinecould be explained by the use of the hydrazine solution at high
temperatures for several hours.
A similar approach was used by Wintereld and Nair on the
racemic 1,2-dicarboxylated piperidine 9, which was treated with
anhydrous hydrazine and sodium ethoxide to obtain the rst
example of a bicyclic aza-DKP 10 in 65% yield (Scheme 4).27
This method was also employed in a patent published in
2002 regarding the synthesis of tadalal analogues as PDE5
inhibitors.28 Thus, from the enantiopure dicarboxylated
precursor 11 and hydrazine, aza-DKP 12 was synthesised as
a tadalal analogue with a 10% yield (Scheme 5).
This strategy was also described by the team of Robba,29–31 to
obtain aza-DKPs fused to diverse N-heterocycles. Starting from
carboxy-3-indazole hydrazide 13 and ethyl chloroformate, the
acyclic precursor 14 was obtained (Scheme 6).29 Then, upon
treatment with KOH, 14 cyclised to the corresponding triazino-
1,2,4-[4,5-b]indazole 15 with a yield of 79%. It can be noted here
that in the nal product, the 1-H-indazole heterocyclic moiety is
replaced by a 2-H-indazole moiety, usually less stable by
a few kcal mol1.32
The same authors then extended their strategy to the
synthesis of other fused aza-DKPs 17 and 19 involving hetero-
cycles such as indoles30 or pyrroles31 (Scheme 7).Scheme 5 Synthesis of an aza-DKP analogue of tadalafil.
Scheme 6 Triazino-1,2,4-[4,5-b]indazole synthesis from a 2-
aminoacetohydrazine.
43360 | RSC Adv., 2020, 10, 43358–43370Pinnen et al. used the monocyclic precursor 20 and rst
switched the Boc-protecting group with a p-nitro-
phenoxycarbonyl by treating 20 sequentially with TFA and the
corresponding aryl chloroformate. The amide function of 21
was then deprotonated by NaH leading aer cyclisation on the
activated carbazate to the lactic acid-derived bicyclic aza-DKP 22
(Scheme 8).33
From the 2-aminoacetohydrazide carbamate derivative 23,
Baudet et al. generated in situ upon treatment with diazo-
methane the isocyanate of an activated carbamate derived from
phenol, 4-nitrophenol or thiophenol (Scheme 9).34 Aer
formation of the isocyanate intermediates 24, the cyclisation
occurred through the attack of the hydrazine on the carbonyl
leading to the aza-DKPs 25 with yields between 78 and 84%.
This strategy was also performed in one single step from a 2-
aminoacetohydrazide using phosgene or one of its syntheticScheme 9 Cyclisation via a masked isocyanate for the synthesis of
aza-DKPs.
Scheme 10 Aza-DKP synthesis using diphosgene.
This journal is © The Royal Society of Chemistry 2020
Scheme 11 Aza-DKP synthesis with one formal step by Beauchemin
et al.



































































































View Article Onlineanalogues. Baraldi and co-workers have been the rst to use
diphosgene for the synthesis of aza-DKPs. It allowed a quick
cyclisation from precursors 27 via the double attack of both
nucleophilic nitrogen atoms to obtain a series of pyrazolo[1,5-
d]-1,2,4-triazines 28 with good yields between 53 and 68%
(Scheme 10).35
Finally, the method described by Beauchemin et al. in 2015
showed the possibility to synthesise a whole series of disubsti-
tuted aza-DKPs 32 through a one-pot sequence in which 30 are
not isolated (Scheme 11).36 The phenol-derived carbazates 29
were rst acylated by chloroacetyl chloride catalysed by pyri-
dine, which cannot trigger the formation of the isocyanate.
Then, the corresponding primary amine and triethylamine were
added to the reaction mixture, the latter being basic enough to
trigger the isocyanates 31 formation and the cyclisation, leading
to the aza-DKPs 32 with global yields of 21 to 77%. It should be
noted that this method was also performed on substrates with
nucleophilic functions present on the hydrazine or the amine
(alcohol, phenol, aniline, pyridine, thiophene, indole.) with
yields from 33 to 73%.
This strategy was also used on solid phase by the team of
Scialdone in 1999.37 Aer xing the desired hydrazine on
a Phoxime® resin, the peptide coupling was performed with
DIC and HOBt to add phenylalanine and to obtain the 2-ami-
noacetohydrazide precursors 35. Aer N-Boc deprotection with
TFA, treatment with Hünig's base allowed isolation of theScheme 12 First example of an aza-DKP synthesis on a Phoxime®
resin.
This journal is © The Royal Society of Chemistry 2020desired aza-DKPs 36 with low yields between 10 and 37%
(Scheme 12).2.2. Via cyclisation of a semicarbazide
The second strategy is based on a semicarbazide (isolated or
not) that can be obtained by one of these three following routes
(Scheme 13): (i) reaction of a hydrazine with an activated N-
carboxylated amino acid derivative I (as an isocyanate or a-lac-
tam); (ii) reaction of an activated carbazate II with an amino
acid derivative III; (iii) reaction of an amino acid derivative III
with a hydrazine and a carbonyl source. The cyclisation of the
semicarbazide through an amide bond formation affords the
corresponding aza-DKPs.
2.2.1. From a hydrazine and a dicarbonylated substrate.
Ethyl isocyanoacetate 37 was used as a nitrogen-containing and
dicarbonylated derivative in a synthesis described by Schwan in
1983.38 By reacting this isocyanate with a symmetrically disub-
stituted hydrazine, the author obtained the semicarbazide 38,
which then cyclised under acidic catalysis, leading to the
desired aza-DKP 39 (Scheme 14).
Furthermore, Hoffman et al. used a-lactams as partners in
the reaction with hydrazines. The a-lactam is obtained in situ
from a N-(mesyloxy)malonamide by treatment with Hünig's
base. Then, this intermediate may easily react by ring-opening
with different amines, even poorly nucleophilic ones such as
dicyclohexylamine, or hydrazines, leading to ureas or semi-
carbazides respectively.39 Thus, different N-(mesyloxy)malona-
mides 40 and diversely substituted hydrazines were used to
obtain aza-DKPs 43 with yields between 52 and 92% (Scheme
15).40
2.2.2. From activated carbazates and amino acids. An
alternative method to the previous one involves activatedScheme 14 Aza-DKP synthesis from an isocyanate.
RSC Adv., 2020, 10, 43358–43370 | 43361



































































































View Article Onlinecarbazates as masked isocyanates for the formation of semi-
carbazides. Pinnen et al.41 used DMAP as a nucleophilic catalyst
to activate the 4-nitrophenyl-carbazate derivative 44 and thus
generate the isocyanate at room temperature. The latter, in the
presence of proline methyl ester, led to the desired semi-
carbazide 45 in 89% yield aer 96 hours (Scheme 16). The cyc-
lisation was performed under HCl catalysis and gave the nal
triazine 46 with a yield of 72%.
From the activated imino carbazate 47 and using Hünig's
base, Lubell et al. obtained the corresponding semicarbazide 48
with a 60% yield while lowering reaction time to 20 hours
(Scheme 17).42 This intermediate was then N-alkylated in clas-
sical conditions with moderate yields to give the desired aza-
DKPs 50 aer the deprotection of the hydrazone and HCl-
catalysed cyclisation.Scheme 16 Aza-DKP synthesis from an activated carbazate.
Scheme 17 Aza-DKP synthesis using an activated carbazate.
43362 | RSC Adv., 2020, 10, 43358–433702.2.3. From hydrazines, amino acids and a phosgene
equivalent. The reaction between phosgene (COCl2) and
a primary amine represents a highly efficient method to form an
isocyanate in situ by action of a base. This method enables the
preparation of a large diversity of isocyanates for a straightfor-
ward access to compounds of interest such as semicarbazides
(Scheme 18).
However, as phosgene is a highly reactive and toxic gas, less
hazardous synthetic analogues were developed to replace it,
such as liquid diphosgene (TCF, trichloromethyl chlor-
oformate) or solid triphosgene (BTC, bis(trichloromethyl)
carbonate). During the synthesis of aza-DKPs from hydrazines
and cyclic amino acids, Obreza and Urleb used this kind of
species to introduce the carbonyl group (C]O) between two
nitrogen atoms of the two partners (Scheme 19).43 Triphosgene
was used and the corresponding semicarbazides 52 were iso-
lated in excellent yields. Aer acid-catalysed Boc-deprotection,
the desired bicyclic aza-DKPs 53 were obtained by cyclisation
through an amidation process.
Based on the same strategy, several aza-DKPs 56 were syn-
thesised from enantiopure amino acids by Ganesan's group in
collaboration with our laboratory.44,45 First, the synthesis was
performed in two steps by isolating the intermediary semi-
carbazide 55 in high yields (Scheme 20). This intermediate was
then cyclised with PPTS or the ion exchange resin Amberlyst 15,
depending on the amino acid employed. These conditions
allowed the L-serine methyl ester 57 to be used as a precursor,Scheme 18 Semicarbazide synthesis using phosgene.
Scheme 19 Synthesis of bicyclic aza-DKPs using triphosgene.
Scheme 20 (a) Aza-DKPs synthesis from enantiopure amino acids; (b)
aza-DKP synthesis from the unprotected L-serine.
This journal is © The Royal Society of Chemistry 2020
Scheme 21 One-pot synthesis of aza-DKPs.
Scheme 22 Aza-DKP synthesis on Wang or HMBA resin (PS ¼
polystyrene).
Fig. 4 Numbering of a tetrasubstituted aza-DKP.


































































































View Article Onlinewithout protecting the hydroxyl function, and the correspond-
ing aza-DKP 59 was obtained in excellent yields (81 and 72%)
without any undesired side-products.
Subsequently, a one-pot version of this strategy was devel-
oped (without isolating the semicarbazide intermediates 61)
using various amino acids (Scheme 21). The crude mixture ob-
tained aer the rst step was directly treated with TFA in water
to give aer cyclisation the desired aza-DKPs 62 with yields
between 27 and 70%.
Compared to the original racemizing reaction conditions
described by Schlögl,26 the milder method enabled access to
chiral semicarbazides and their corresponding triazines.
Although, no evidence regarding the absence of a partial race-
misation has been described, this strategy still represents
a signicant step towards the synthesis of chiral aza-DKPs.
Furthermore, the same authors transferred this strategy
towards solid phase synthesis (Scheme 22).44 This method
allowed a rapid synthesis of diverse derivatives without inter-
mediate purication. Wang or HMBA resins were selected in
order to start the synthesis with the desired amino acid directly
attached to the solid support. Aer Fmoc-deprotection and
reductive amination, the amino acids 65 was acylated with tri-
phosgene leading to the corresponding carbamoyl chlorides 66.
This intermediate was then reacted with different tert-butyl
carbazate derivatives to obtain the desired semicarbazides 67.
Upon treatment with TFA in water, the semicarbazides led to
the corresponding aza-DKPs 68 in solution with yields between
9 and 78% for Wang resin and 53 to 93% for HMBA resin.Scheme 24 Variation of the substituent at position 4 with a reductive
amination.3. Aza-DKP structural variation
The variation of the substituents at the four positions of an aza-
DKP structure (Fig. 4) may be performed either during theirThis journal is © The Royal Society of Chemistry 2020synthesis through the different strategies presented previously
or by post-functionalisation.3.1. Variation during the synthesis
This strategy is based on the introduction of the desired
substituent during the aza-DKP synthesis, by selecting the
suitable reactive partners, according to the strategy employed
(cf. § 2).
3.1.1. Variation at positions 4 and 5. The rst category of
variations can be performed at positions 4 and 5 of the
heterocycle. The position 5 represents a key element for the
structural diversication of aza-DKPs. The substituent placed at
this position can originate from natural enantiopure amino
acids used as precursors in several strategies (cf. § 2.2.3.,
Schemes 20 and 21).44,45 Thus, different groups (alkyl, benzyl, or
functionalised chains) have been varied at position 5 of an aza-
DKP to obtain 70a–e with the conservation of the amino acid
enantiopurity (Scheme 23).
The substituent at position 4, linked to the nitrogen, was also
modied during the syntheses of aza-DKPs. For instance, benzyl
groups have been introduced at this position (cf. § 2.2.3.,
Scheme 19), from N-benzylated amino acids previously ob-
tained by a reductive amination on 71 (Scheme 24).44RSC Adv., 2020, 10, 43358–43370 | 43363
Scheme 25 Variation of the substituent at position 4 with primary
amines.



































































































View Article OnlineThis substituent was also diversied thanks to another
strategy introducing a primary amine bearing this substituent
before cyclisation (cf. § 2.1., Scheme 11).36 Indeed, a large
number of aza-DKPs (75) have been synthesised from
commercially available primary amines (Scheme 25).
In the bicyclic aza-DKP series, positions 4 and 5 can also be
linked together. Structures such as 77 can be obtained from
suitable cyclic amino acid precursors 76 such as L-proline,
pipecolinic acid or thiaproline (Scheme 26). The different
methods used to synthesise such bicyclic systems were previ-
ously detailed (cf. § 2.1., Scheme 4; § 2.2.2., Schemes 16 & 17; §
2.2.3., Schemes 19–22).27,41–45
Finally, bicyclic aza-DKPs 79 fused to N-heterocycles have
also been obtained (Scheme 27). The precursors used in these
cases included the corresponding heterocycle (indazole, pyrrole
or pyrazole) in their structure (cf. § 2.1., Schemes 6, 7 and
10).29–31,35
3.1.2. Variation at positions 1 and 2. Positions 1 and 2
relate to the substituents linked to the nitrogen atoms of theScheme 26 Bicyclic aza-DKPs: Variation of substituents at positions 4
and 5.
Scheme 27 Aza-DKPs fused with N-heterocycles.
43364 | RSC Adv., 2020, 10, 43358–43370hydrazine moiety. Amongst the synthetic methods previously
described, several included a reaction between hydrazine and
a carboxylated derivative. To avoid any regioselectivity issues,
symmetric hydrazines 80 were rst used (cf. 2.1., Schemes 3–7 &
9; cf. § 2.2.1, Scheme 14).26–31,34,38 Thus several aza-DKPs 81
having identical substituents on nitrogen atoms N1 and N2
were obtained (Scheme 28).
The modication of the substituent at position 2 was also
performed through different strategies, either by using mono-
substituted hydrazines or 1,2-disubstituted hydrazines with one
nitrogen atom being deactivated by a protecting group. For
instance, the phenyl group was introduced by phenylhydrazine,
the regioselectivity being controlled by deactivation of the N-
phenyl nitrogen through mesomeric effect (cf. § 2.1., Scheme
10).35 Using a particular hydrazine bearing on one side the
desired substituent while the other is deactivated by a Boc
protecting group, the formation of the semicarbazide precursor
of the desired triazine was regioselective (cf. § 2.2.3., Schemes 20
and 21).44,45 Another method used a hydrazone-protection for
one of the nitrogen atoms while the other was deprotonated in
order to introduce the desired substituent by N-alkylation (cf. §
2.2.2., Scheme 17).42 This way alkyl, allyl, propargyl, benzyl, or
phenyl groups have been introduced at position 2 during the
synthesis of the corresponding aza-DKPs 83 (Scheme 29).
Finally, the substituent at position 1 can also be varied using
monosubstituted hydrazines 84. In a similar way, the regiose-
lectivity of the reaction involving hydrazine can be controlled by
decreasing the nucleophilicity of the nitrogen bearing the
desired substituent by steric or electronic effects (cf. § 2.1.,
Schemes 11 and 12; cf. § 2.2.1., Scheme 15).36,37,40 Thereby,
several groups (alkyl, benzyl, aryl) have been introduced duringScheme 29 Substituents variation at position 2.
This journal is © The Royal Society of Chemistry 2020
Scheme 30 Substituents variation at position 1.


































































































View Article Onlinethe synthesis of the corresponding aza-DKPs 85 on nitrogen N1
(Scheme 30).
Table 1 below summarizes the variations at the four posi-
tions of an aza-DKP, according to the precursor involved and the
strategy employed, with the corresponding references from the
literature.3.2. Variation by post-functionalization
This strategy is based on the introduction or the modication of
the substituents aer the cyclisation step and has been devel-
oped by our team for the generation of aza-DKPs that cannot be
easily obtained otherwise.
3.2.1. Modication of the substituent in 1- and/or 2-posi-
tions. Aza-DKPs 86 bearing either an allyl or a homoallyl group
at position 2 were prepared in our laboratory (cf. § 2.2.3.,
Scheme 21). The double bond present in these structures could
then be modied by a rhodium-catalysed hydroformylation,
introducing regioselectively a formyl group at the terminal
position. The aldehyde intermediate obtained was thenTable 1 Synthetic strategies for the variation of the substituents at the f






1 & 2 (R1 ¼ R2 ¼ R) 2.1 NH




3 & 4 2.1
3 & 4 2.1
3 & 4 2.2.2
3 & 4 2.2.3
This journal is © The Royal Society of Chemistry 2020engaged in a cyclisation process through an intramolecular
condensation reaction on the nitrogen atom N1 leading to the
corresponding bicyclic aza-DKPs 88 with yields between 57 and
81% (Scheme 31).45 This cyclohydrocarbonylation strategy
allowed the synthesis of a new series of bicyclic aza-DKPs fused
with 6- or 7-membered rings on the hydrazine moiety.
Furthermore, this process resulted in the formation of a cyclic
enamide, with the double bond offering new opportunities for
post-synthetic transformations.
The reactivity of the enamide was at rst exploited to intro-
duce functions at the a-position to the nitrogen. For instance,
when reacted with a nucleophile such as methanol in acidic
medium (CSA), aza-DKPs 89 led to the corresponding chiral
hemiaminal ethers 90 with yields between 61 and 86%. Dia-
stereomeric ratios were higher than 93/7 for 90a–d and about
37/63 for aza-DKP 90e fused with a 7-membered ring (Schemeour positions of an aza-DKP
ecursor Scheme Ref.




NH–NHZ 20 and 21 44 and 45
2–NH2 3–7 26–31
H–NHR 9 and 14 34 and 38
NH2 11 36
NHCH(R4)CO2R 20 and 21 44 and 45
NHCH(R4)CO2R 20 and 21 44 and 45
4 27
6 and 7 29 and 31
16 and 17 41 and 42
19–22 43–45
RSC Adv., 2020, 10, 43358–43370 | 43365
Scheme 32 Introduction of a methoxy group on a bicyclic aza-DKP.
Scheme 33 Domino cyclohydrocarbonylation/MeOH addition for the
synthesis of bicyclic aza-DKP 90a.



































































































View Article Online32).45 Aza-DKP 90a was also obtained through a one-pot process,
from the N-allyl aza-DKP 91, in cyclohydrocarbonylation
conditions with methanol as a co-solvent. The yield as well as
the diastereomeric ratio obtained in this case (74%, 93/7) were
similar to the one obtained in the two-step process (Scheme
33).45
A multicomponent process including the formation of the
triazine ring was also developed to obtain aza-DKPs. The linear
precursor placed in cyclohydrocarbonylation conditions in the
presence of a nucleophile (ROH, TMSCN, nPrSH) and
a Brønsted (CSA) or Lewis acid (BF3), semicarbazides 92 led
directly to the corresponding aza-DKPs 90 and 93 (Scheme 34).46Scheme 34 One-pot synthesis of bicyclic functionalised aza-DKPs.
43366 | RSC Adv., 2020, 10, 43358–43370Treatment of the hemiaminal ether 90a with other nucleo-
philes under BF3$Et2O catalysis allowed the introduction of
several functions at the a-position to the nitrogen (Scheme 35).45
The use of trimethylsilyl cyanide (TMSCN) for instance allowed
the introduction of a nitrile group at this position with a yield of
92% and a modest diastereomeric ratio of 68/32. The acidic
hydrolysis of the major diastereomer gave the corresponding
carboxylic acid 96 in 69% yield. In similar conditions, trime-
thylsilyl azide (TMSN3) allowed the addition of an azide func-
tion at this position in 88% yield and an excellent
diastereomeric ratio (>95/5). The catalytic hydrogenation of 94
in the presence of di-tert-butyl dicarbonate (Boc2O) led to the
corresponding carbamate 95 with a yield of 86%.
Aza-DKP 97 was also studied as an endocyclic enamide
partner in the Povarov reaction in order to perform a formal
difunctionalisation of the double bond (Scheme 36).47 This
reaction was catalysed by BF3$Et2O and was performed either
with the iminodiene partner (2CPR) or directly with an aniline
derivative and an aldehyde via a three component Povarov
reaction (3CPR). Aliphatic and electron-decient aromatic
aldehydes were rather successfully used while electron poor or
rich anilines could also be employed for this reaction. The
Povarov adducts 98-endo and 98-exo were obtained in yields
between 18 and 94% and diastereomeric ratios between 50/50
and >99/1, the diastereomers being separable by reversed-
phase chromatography. The mechanistic aspects of this reac-
tion were studied computationally.
3.2.2. Modication of the substituent in 5-position. The
structural modication of the substituent in the 5-position of
the aza-DKP has so far only been studied by our laboratory.Scheme 36 Quinoline formation via a Povarov reaction on a endo-
cyclic enamide.
This journal is © The Royal Society of Chemistry 2020
Scheme 37 Hydroxyl substitution with an azide at position 5 of an aza-
DKP.
Scheme 39 Azide reduction and amine functionalisation.


































































































View Article OnlineFrom the serine-derived aza-DKP 99, palladium-catalysed
hydrogenation and hydrogenolysis allowed us to obtain
directly aza-DKP 100. The hydroxyl was substituted by an azide
via a tosylate, leading aer acid-promoted deprotection to the
aza-DKP 103 with a good yield (Scheme 37).48
Aerwards, the azide moiety on the aza-DKP 103 was trans-
formed through copper(I)-catalysed cycloaddition with several
terminal alkynes, into the corresponding triazoles 104with high
yields (Scheme 38).
Starting from the same precursor 103, the azide function was
also reduced to the amine via palladium-catalysed hydrogena-
tion. The resulting aza-DKP 105 was then N-acylated using
different methods (Scheme 39). Using acyl chlorides led to the
corresponding amides 106a–c with yields between 77 and 93%
(Scheme 39). Peptide coupling conditions allowed access to aza-
DKPs 106d–e coupled with L- and D-phenylalanine with respec-
tive yields and diastereomeric ratio of 84% (dr ¼ 94/6) and 96%
(dr¼ 93/7). A slight partial racemisation had occurred during the
synthesis of the azide 103, as the second diastereomer was
observed. Moreover, the treatment of amine 105 with Boc2O led
to the corresponding carbamate 106f in 94% yield.48
Finally, under Mitsunobu conditions, aza-DKP 100 previ-
ously obtained was dehydrated to give the corresponding
product 107 with an exocyclic double bond, in 91% yield
(Scheme 40).48
3.2.3. Introduction of a substituent in 4-position. Studies
from our laboratory also focused on the post-functionalisation
of the position 4 of the heterocycle. The alkylation of the aza-
DKP 106a with bromide derivatives was performed in the
presence of a phosphazene-type, non-nucleophilic, strong baseScheme 38 Triazole formation at position 5 via Cu-catalysed [3 + 2]
cycloaddition.
This journal is © The Royal Society of Chemistry 2020(BEMP) and allowed us to introduce several alkyl, propargyl and
benzylic substituents on the position 4 of the enantiopure aza-
DKPs 108 with yields between 11 and 89% (Scheme 41).48
To perform the N-acylation in 4-position of the bicyclic aza-
DKP 109, Pinnen et al. used the acyl chloride derived from O-Scheme 41 N-Alkylation at position 4.
Scheme 42 N-Acylation at position 4 with an acyl chloride.


































































































View Article Onlinebenzyl lactic acid, in the presence of pyridine (Scheme 42).33
This method led to aza-DKP 22 in only 15% yield, which was
lower than that obtained by the same authors when the acyl
group was introduced before the cyclisation step (cf. Scheme 8).Fig. 5 2D plot of current drug-like scaffold space (reproduced from
Org. Biomol. Chem., 2016, 14, 8859).
Fig. 6 Aza-DKP structure with potential crop protection activity.
Fig. 7 Structures and activities of tadalafil and an aza-DKP analogue.
Table 3 Structures and cytotoxicity of an aza-DKP candidate 113
compared to doxorubicin 1144. Aza-DKP physicochemical
properties and biological activities
Although studies focused on aza-DKPs’ physicochemical and
biological properties are less extensive compared to their more
common DKP counterparts, nevertheless they have shown
promising results.
Recently, we evaluated the chemical space occupied by aza-
DKPs and their “drug-likeness” properties by determining the
quantitative estimate of the drug-likeness (QED).46 Thus, the
radius of gyration (ROG) was plotted as a function of the frac-
tion of sp3-hybridised carbons (Fsp3) of aza-DKP skeletons D
and E and compared with more than 9000 unique structures
described in the literature (Fig. 5).46 This analysis showed thatTable 2 Physicochemical properties comparison of an aza-DKP and
its DKP equivalent
Compound Aza-DKP 5 DKP 4
Solubility (mM) 16.5  0.6 1.0  0.1
Log D 1.1  0.1 1.4  0.1
Stability (%) PBS (25 C, 24 h) >98 >98
Plasma (37 C, 6 h) >98 >98
Microsomes (37 C, 30 min) 83  3 51  1
43368 | RSC Adv., 2020, 10, 43358–43370both structures D and E were found in an under-populated area
of the graph, demonstrating that a new chemical space can be
explored with these new structures. Furthermore, both D and E
exhibited high Fsp3 values (0.75) which allows a larger panel
of decorating substituents around the scaffold while keeping
this value high enough to improve their probability to
successfully go through the different stages of clinical trials.49
Our group also compared the physicochemical properties of
aza-DKP 5 and its DKP equivalent 4. The aza-DKP studied
exhibits a 16-fold higher aqueous solubility in PBS than the
corresponding DKP (Table 2).46 Compound 5 also shows a lower
log D 7.4 than 4 enabling the introduction of apolar substitu-
ents around the core during the drug discovery process. Finally,
although both structures exhibited similar stability in PBS or
mouse plasma, a higher metabolic stability was observed for
aza-DKP 5 in mouse liver microsomes (83% vs. 51% ofCompound
IC50 (mM)
CCRF-CEM CCRF_SB MT-4 HT-29
rac-113 0.002 0.002 0.005 1.01
114 0.02 0.03 0.01 0.01
Compound
IC50 (mM)
MCF-7 HeLa ACHN SF-268 XF-498
rac-113 0.55 0.61 0.65 3.55 4.80
114 0.05 0.07 0.04 0.2 0.16


































































































View Article Onlineremaining molecules aer 30 minutes in the presence of
microsomes). These observations, if extrapolated, show better
drug-like properties for these heterocycles compared with
DKPs, a family of molecules already well known in medicinal
chemistry.5
Regarding biological activities, only three studies including
aza-DKPs have been reported to date. A team at Ciba–Geigy rst
described an aza-DKP 110, in a patent about pyridine derivatives
as pesticides, without specifying its activity (Fig. 6).50
Another patent published by a team at Lilly in 2002, focusing
on tadalal analogues, also synthesised aza-DKP 112 (Fig. 7).28
This molecule exhibited an inhibitory activity against PDE5,
lower than that of tadalal 1 (113 nM vs. 5 nM).51 Nevertheless,
this example shows that the DKP to aza-DKP switch did not lead
to a dramatic reduction of the activity prole, and may be
compensated by pharmacokinetic gains such as aqueous solu-
bility or stability.
Finally, both the groups of Bolognese and Lavecchia focused
on an aza-DKP series as potential anti-cancer drugs (Table 3).52
The spiro-fused aza-DKP ()-113 emerged from this series as
the most promising example with its high activity against
several cancer lines (CCRF-CEM, CCRF-SB, MT-4) especially
when compared with doxorubicin 114.5. Conclusions
In this review we highlight the interest of aza-DKPs as potential
alternative to the well-known DKPs. Several different synthetic
strategies have been developed since the rst example pub-
lished by Schlögl and Korger in 1951. Many variations around
the aza-DKP core have also been made during their synthesis or
by post-functionalisation to reach the corresponding mono-, di-
, tri- or tetra-substituted aza-DKPs. Therefore a wide variety of
these structures is currently available occupying a new drug-like
scaffold space. These 3D-shaped heterocycles with one or more
sp3-hybridized carbons including stereocenters display prom-
ising physicochemical and biological properties. Thus, the
replacement of one carbon-stereogenic center of a DKP by
a nitrogen atom results in a signicant increase of their water
solubility and microsomal stability. The different accesses to
chiral aza-DKPs starting from amino acid precursors combined
with the range of substitution patterns available around the
ring, should fuel further interest in the synthesis of these
triazines and the investigation of their potential in chemical
biology and drug discovery.Conflicts of interest
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